Psychedelics Investing

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Psychedelics Investing

Goodness Growth Holdings Announces First Quarter 2024 Results

Psychedelics Investing

Notice of Annual General Meeting/Proxy Form

Psychedelics Investing

Goodness Growth Holdings Announces Filing of Application for Summary Determination in Litigation with Verano

Psychedelics Investing

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Psychedelics Investing

Goodness Growth Provides CREAM & Fire Updates

Psychedelics Investing

Quarterly Activities Report: Melodiol Delivers $4.4M in Revenue during Q1 FY24 – a 91% Increase the PCP

Psychedelics Investing

Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations

Psychedelics Investing

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Psychedelics Investing

Q1 FY24 Revenue Update

Psychedelics Investing

Psychedelics Outlook Report

Psychedelics Investing

Latest psychedelics News

More psychedelics News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES
×